Updates in Atrial Fibrillation ACC/AHA Guidelines

HEATHER MURPHY-LAVOIE, MD

RECOGNITION

THANK YOU TO Chief resident PAUL RAMIREZ FOR IDEA, SOME SLIDES AND INSPIRATION FOR THIS TALKI AND INSPIRATION FOR THIS TALKI




OBJECTIVES

- REVIEW LATEST GUIDELINES FOR THE MANAGEMENT OF ATRIA FIBRILLAITON
- DEVELOP STRATEGIES FOR INCORPORATING EVIDENCE INTO BEST PATIENT CARE
- RECONGIZE THE INDICATIONS FOR CARDIOVERSION AND ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION

CLINICAL SCENARIO

- 55 year old woman presents to the ED complaining of palpi and fatigue for 2 days. She denies chest pain, SOB, fever.
- No PMHx
- Bp135/80, HR 106, RR 18, Temp 98.8, Sat 99% on RA
 EKG Atrial Fibrillation at 106



2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of **Atrial Fibrillation**

A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Developed in Collaboration With and Endorsed by the American College of Clinical Pharmacy and the Heart Rhythm Society

Electrical Cardioversion

COR	LOE	RECOMMENDATIONS
1	C-LD	 In patients with hemodynamic instability attributable to AF, immediate electrical cardioversion should be performed to restore sinus rhythm.¹
1	B-R	2. In patients with AF who are hemodynamically stable, electrical cardioversion can be performed as initial rhythm-control strategy or after unsuccessful pharmacological cardioversion. ²
1	C-LD	3. In patients with AF undergoing electrical cardioversion, energy delivery should be confirmed to be synchronized to the QRS to reduce the risk of inducing VF. 3
Za	B-R	4. For patients with AF undergoing elective electrical cardioversion, the use of biphasic energy of at least 200 J as initial energy can be beneficial to improve success of initial electrical shock. ^{4,5}
Za	B-NR	5. In patients with AF undergoing elective cardioversion, with longer duration of AF or unsuccessful initial shock, optimization of electrode vector, use of higher energy, and pretreatment with antiarrhythmic drugs can facilitate success of electrical cardioversion. ⁵⁻⁹
		-
2b	C-LD	6. In patients with obesity and AF, use of manual pressure augmentation and/or further escalation of electrical energy may be beneficial to improve success of electrical cardioversion. ¹⁰

Prevention of Thromboembolism in Setting of Cardioversion

 In patients with AF duration of ≥48 hours, a 3-week duration of uninterrupted therapeutic anticoagulation
or imaging evaluation to exclude intracardiac thrombus is recommended before elective cardioversion.¹ B-R 2. In patients with AF undergoing cardioversion, therapeutic anticoagulation should be established before cardioversion and continued for at least 4 weeks afterwards without interruption to prevent thrombo-ambuliem $^{2/2}$ B-NR

- Big change here is that 2014 guidelines stated that patient were cardioverted should be anticoagulated following cardioversion based on thromboembolic risk.
 Recommend anticoagulating high-risk patients.
- Now, they are now giving a more uniform recommendation to anti-coagulate everyone for at least 4 weeks!

Prevention of Thromboembolism in Setting of Cardioversion

26	C-LD	on anticoagulation, those who are at el
25	C-LD	 In patients with low hours, the benefit of

ported AF duration of <48 hours (not in the setting of cardiac surgery) and who are not , precardioversion imaging to exclude intracardiac thrombus may be considered in slevated thromboembolic risk (CHA₂DS₂-VASc score ≥2 or equivalent).^{71,22} Concern for underestimation of particular to the theorem of the transformation of t

- No clear recommendations on patients with CHA2DS2-VASc of 0 or 1 and Afib duration >12 hours.

		LOIL	e Risł		
C HF +1			Score	Score Risk of stroke	
Hypertension	+1		0	0.2%	Low
A ge ≥75	+2		1	0.6%	Moderate
Diabetes	+1		2	2.2%	High
Diabelles			3	3.2%	
Stroke/TIA/VTE	+2		4	4.8%	1 3 1
			5	7.2%	
Vascular Disease	+1		6	9.7%	
A ge 65-74	+1		7	11.2%	l 🔊
ALEC UD-1-1			8	10.8%	
Sex (female)	+1		9	12.2%	

_		

Take Home Points for Electrical Cardioversion

- Synchronized cardioversion is first line therapy for unstable patients in which instability is attributed to the atrial fibrillation.
- Consider cardioversion for stable patients with atrial fibrilla
 Patients need anticoagulation before cardioversion if >48 symptoms.

- Anticoagulate for 4 weeks after cardioversion.
 Consider imaging prior to cardioversion if not on anticoagulation and high risk for thromboembolism even if symptoms <48 hours.

Overview of Pharmacological Conversion of Atrial Fibrillation



Pharmacological Conversion

- For patients with AF, pharmacological cardioversion is reasonable as an alternative to electrical cardioversion for those who are hemodynamically stable or in situations when electrical cardioversion is preferred but cannot be performed.¹ C-LD
- No studies comparing electrical vs pharmacological cardi in patients who are unstable.
- In stable patients, pharmacological cardioversion was less than electrical cardioversion.

LOE

Pharmacological conversion may be preferred in patients who cannot easily undergo electrical cardioversion such as if they cannot tolerate anesthesia.

Pharmacological Conversion -Ibutilide and Amiodarone

- For patients with AF, ibutilide^{2,3} is reasonable for pharmacological cardioversion for patients without depressed LV function (LVEF <40%). For patients with AF, intravenous amiodarone is reasonable for pharmacological cardio time to conversion is generally longer than with other agents (8-12 hours).⁴⁻⁸
- 2a

ersion, althoug

- Ibutilide is effective at converting to sinus rhythm effectively 30-90 minutes but there is increased risk of Tosades de Point QTc prolongation.
- Multiple RCTs have found IV Amiodarone is effective for pharmacological conversion, but it is generally slower than ibutilide.

Pharmacological Conversion -Procainamide


BR 5. For patients with AF, use of intravenous procainamide may be considered for pharmacological cardio-version when other intravenous agents are contraindicated or not preferred.¹⁹ 25

- IV procainamide is more effective than placebo for convesions rhythm. (conversion rates at 1 hour, 69% vs 38%).
- IV procainamide is less effective than ibutilide at conversio sinus rhythm.
- Patients can experience hypotension and drug can exacerbate HFrEF.

Take Home Points for Pharmacological Conversion

- Pharmacological conversion is effective although less so the electrical cardioversion.
- Ibutilide is effective and fast but <u>cannot</u> be used in patients with HFrEF and may cause Torsades! Amiodarone is effective but slower and can be used in a w
- Procainamide is an option but it appears less effective than ibutilid

Overview of Acute Rate Control of Atrial Fibrillation



Acute Rate Control – BB/CCB

In patients with AF with rapid ventricular response who are hemodynamically stable, beta blockers or nondihydropyridine calcium channel blockers (verapamil, ditiazem; provided that EF >40%) are recommended for acute rate conto (Figure 17).¹⁴

- You can use either beta blockers or CCB for acute rate co

LOE RECOMMENDATIONS

- Metoprolol Tartrate IV 2.5-5 mg bolus over 2 min; up to 3 doses
 Esmolol So0mg/kg bolus over 1 min; then 50-300mg/kg/min
 Diltiazem 0.25 mg/kg (actual body weight) IV over 2 min; May repeat 0.35 mg/kg over 2 min; then 5-15 mg/n continuous infusion

Acute Rate Control - Magnesium

- In patients with AF with rapid ventricular response, the addition of intravenous magnesium to stand rate-control measures is reasonable to achieve and maintain rate control.^{10,11}

Mechanism is likely blockade of slow inward calcium channels in SA and AV nodes slowing heart rate and causing conduction delay. Low side effect profile and generally well tolerated Meta-analysis of 6 RCTs looking at IV magnesium given in combine with standard rate control medications compared to standard meta control medications compared to standard meta. Improved rate control (63% versus 40%: OR. 2.49 [95% CI, 1.80-3.45])

Modest improvement at conversion to sinus rhythm (21% versus 14%; OR, 1.75 [95% CI, 1.08-2.84])

2a A

There was superiority in subgroup analysis for <5g (24% versus 13%) compared to >5g (16%versus13%) for rhythm control compared to placebo.

Acute Rate Control - Amiodarone

4. In patients with AF with rapid ventricular response who are critically ill and/or in decompensated HF in whom beta blockers and nondihydropyridine calcium channet blockers are ineffective or contraindicated, intravenous amiodarone may be considered for acute rate control.^{12,13} 2b B-NR

- One retrospective study of 38 ICU patients compared amiod diltiazem or digoxin.
- Significant decrease in heart rate without decrease in 8P using annuare Another study of 60 critically ill patients with heart rate >120 in Afib compared allt bolus + influsion, amiodarone bolus, and amiodarone bolus + influsion.
- Sufficient rate control achieved with both drugs.
 Diltiazem had more hypotension requiring discontinuation.
 Dosing: 150-300 mg IV over 1 h, then 10-50 mg/h over 24 h

Acute Rate Control - Digoxin

 In patients with AF with rapid ventricular response in whom beta blockers and nondihydropyridine cal-cium channel blockers are ineffective or contraindicated, digosin can be considered for acute rate control either alone or in combination with the aforementioned agents.⁶⁻⁹ 2a B-R

- Other agents may be safer and more effective.
 In multiple small RCTs, both IV dilfiazem and IV amiodarone were more
 at achieving rate control
- One small RCT which compared IV dilliazem and digoxin vs IV dilliazem whice showed improved rate control with combination.
 Dosing recommendations:
- Onset of action is significantly slower than other agents but it is more hemodynamically neutral.

Acute Rate Control – CCB & HFrEF

- In patients with AF with rapid ventricular response and known moderate or severe LV systolic dysfunction with or without decompensated HF, intravenous nondihydropyridine calcium channel blockers should not be administered.^{14,13} B-NR
- Key difference is recommendation of harm <u>with or without</u> decomp Heart Failure.
- Heart Failure. Due to presumed negative ionatropic effects of CCBs. Retrospective chart review of 635 patients who received IV dilitazem increased rates of AXI for patients with EF <50% compared to normal EF Second retrospective review of 125 patients comparing CCB to BB No difference in total advence events Increased incidence of warseing H symptoms defined as increasing 02 requirement or inhibition of ionatropic suppart. Neithers study showed of lifferences in in-hospital mortality, need for higher level of care, or hypotension.

rm 🛛

Take Home Points for Rate Control

- For stable patients without a history of HFrEF, either beta blocker calcium channel blockers are effective options.
- IV magnesium is a low risk medication that may help with both rate and rhythm control.
- Consider amiodarone or digoxin for patients in who beta and calcium channel blockers are ineffective or contrained
- Calcium channel blockers should not be used in HFrEF regard whether or not there is decompensation.

CLINICAL SCENARIO

- 55 year old woman presents to the ED complaining of interr palpitations and fatigue for 2 days. She denies chest pain, s fever.

Special Populations

- WPW A. Fib with wide complex rate 170—300, needs cardioversion or procainamide, all else might kill
- Rate is not from A. Fib dehydration, sepsis, thyrotoxicosis
 Severe valvular disease or artificial valve should be anticoaguid with Coumadin, everyone else DOAC preferred

Score > bleedii	> 2, increased ng	d risk of	
	Condition	Points	
	H – Hypertension	1	
	A – Ab(N) liver/renal	1 point each	
	S – Stroke	1	
	B – Bleeding	1	
	L – Labile INRs	1	
	E – Elderly (>65)	1	
	In Drugs or ETOH	1 point each	

		rok	e Risk	2	
C HF +1			Score	Risk of stroke	
Hypertension	+1		0	0.2%	Low
A ge ≥75	+2		1	0.6%	Moderate
Diabetes	+1		2	2.2%	High
Diabetes	71		3	3.2%	
Stroke/TIA/VTE	+2		4	4.8%	
			5	7.2%	
Vascular Disease	+1		6	9.7%	
A ge 65-74	+1		7	11.2%	M N
A60 00-14			8	10.8%	
Sex (female)	+1		9	12.2%	



WPW

- mullumaamaan
- ш
- ա

Final Thoughts

- If tachycardic is there another reason that should be treated prior ta rate control?

- Should they be cardioverted? Anticoagulate 3 weeks before an also anticoagulated for 4 weeks!
- Appropriate follow up with cardiology for cardioversion/ablation, monitoring